RE: Trading update7 Feb 2026 13:44
The main risk here seems to be further weakness in consumer spend, particularly the lower end of the income band where W7 operate, and the impact on those new rollouts. Christmas this year was patchy and W7 were increasing prices into Q4. The US was flagged in the last update, I’m not sure how much worse that could get, it was a small revenue contribution but probably higher margin like the US always seems to be. It looks like Bodycare was bought out and is going to reopen up to 50 stores later this year so that could be some upside
Given shorts and generally persistently poor sentiment towards AIM even a slight miss and weakening outlook could be nasty. Saying that, an outlook with a few percent revenue growth could send it back over 250p. Consensus is for a lift in sales from £109m in 2026 to £117m in 2027 and a 10% lift in EBITDA.
The board expects revenues of between £107 million and £112 million, and adjusted EBITDA of between £23.5 million and £25.5 million for the full year 2025.